针对鼠疫耶尔森菌感染的中和嵌合抗 F1 单克隆抗体

IF 4.9 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Antimicrobial Agents Pub Date : 2024-10-08 DOI:10.1016/j.ijantimicag.2024.107354

Xi Wang, Qing Xie, Ying Huang, Jiansheng Lu, Lei Chen, Jiazheng Guo, Yujia Jiang, Qinglin Kang, Xinrui Yu, Wei Zhang, Meng Lv, Lingfei Hu, Rong Wang, Zhixin Yang, Tao Zheng

{"title":"针对鼠疫耶尔森菌感染的中和嵌合抗 F1 单克隆抗体","authors":"Xi Wang, Qing Xie, Ying Huang, Jiansheng Lu, Lei Chen, Jiazheng Guo, Yujia Jiang, Qinglin Kang, Xinrui Yu, Wei Zhang, Meng Lv, Lingfei Hu, Rong Wang, Zhixin Yang, Tao Zheng","doi":"10.1016/j.ijantimicag.2024.107354","DOIUrl":null,"url":null,"abstract":"Drug-resistant Yersinia pestis (Y. pestis) poses a threat to the use of antibiotics to treat Y. pestis infections. Passive immunization with neutralizing monoclonal antibodies (mAbs) is one approach to the treatment of infectious diseases. In this study, a murine single-chain fragment variable (scFv) phage antibody library targeting the F1 antigen was constructed and screened. Therapeutic intravenous injection of 400 μg chimeric mAb S1 through tail veins provided complete protection against Y. pestis (strain: 91001) challenge in a pneumonic plague mouse model. Timely antibody treatment eliminated the bacteria and reduced lung inflammation. Our data suggest that chimeric mAb S1 is a candidate treatment for Y. pestis infection that warrants further study.","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neutralizing Chimeric Anti-F1 Monoclonal Antibody against Yersinia pestis Infection.\",\"authors\":\"Xi Wang, Qing Xie, Ying Huang, Jiansheng Lu, Lei Chen, Jiazheng Guo, Yujia Jiang, Qinglin Kang, Xinrui Yu, Wei Zhang, Meng Lv, Lingfei Hu, Rong Wang, Zhixin Yang, Tao Zheng\",\"doi\":\"10.1016/j.ijantimicag.2024.107354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Drug-resistant Yersinia pestis (Y. pestis) poses a threat to the use of antibiotics to treat Y. pestis infections. Passive immunization with neutralizing monoclonal antibodies (mAbs) is one approach to the treatment of infectious diseases. In this study, a murine single-chain fragment variable (scFv) phage antibody library targeting the F1 antigen was constructed and screened. Therapeutic intravenous injection of 400 μg chimeric mAb S1 through tail veins provided complete protection against Y. pestis (strain: 91001) challenge in a pneumonic plague mouse model. Timely antibody treatment eliminated the bacteria and reduced lung inflammation. Our data suggest that chimeric mAb S1 is a candidate treatment for Y. pestis infection that warrants further study.\",\"PeriodicalId\":13818,\"journal\":{\"name\":\"International Journal of Antimicrobial Agents\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Antimicrobial Agents\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijantimicag.2024.107354\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijantimicag.2024.107354","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

抗药性鼠疫耶尔森菌（Y. pestis）对使用抗生素治疗鼠疫耶尔森菌感染构成了威胁。使用中和单克隆抗体（mAbs）进行被动免疫是治疗传染病的一种方法。本研究构建并筛选了以F1抗原为靶标的小鼠单链片段可变（scFv）噬菌体抗体库。通过尾静脉注射 400 μg 嵌合 mAb S1，可在肺鼠疫小鼠模型中提供针对鼠疫酵母菌（菌株：91001）挑战的完全保护。及时的抗体治疗可消灭细菌并减轻肺部炎症。我们的数据表明，嵌合 mAb S1 是一种治疗鼠疫 Y. 感染的候选药物，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neutralizing Chimeric Anti-F1 Monoclonal Antibody against Yersinia pestis Infection.

Drug-resistant Yersinia pestis (Y. pestis) poses a threat to the use of antibiotics to treat Y. pestis infections. Passive immunization with neutralizing monoclonal antibodies (mAbs) is one approach to the treatment of infectious diseases. In this study, a murine single-chain fragment variable (scFv) phage antibody library targeting the F1 antigen was constructed and screened. Therapeutic intravenous injection of 400 μg chimeric mAb S1 through tail veins provided complete protection against Y. pestis (strain: 91001) challenge in a pneumonic plague mouse model. Timely antibody treatment eliminated the bacteria and reduced lung inflammation. Our data suggest that chimeric mAb S1 is a candidate treatment for Y. pestis infection that warrants further study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Antimicrobial Agents 医学-传染病学

CiteScore

21.60

自引率

0.90%

发文量

176

审稿时长

36 days

期刊介绍： The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.